Literature DB >> 10356019

Economic Notes: opportunity cost.

S Palmer1, J Raftery.   

Abstract

Mesh：

Year:  1999        PMID： 10356019      PMCID： PMC1115911          DOI： 10.1136/bmj.318.7197.1551

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  5 in total

1.  A practical guide for calculating indirect costs of disease.

Authors:  M A Koopmanschap; F F Rutten
Journal:  Pharmacoeconomics       Date:  1996-11       Impact factor: 4.981

2.  Opportunity costs in modern medicine.

Authors:  L B Russell
Journal:  Health Aff (Millwood)       Date:  1992       Impact factor: 6.301

3.  Indirect cost in economic evaluation: the opportunity cost of unpaid inputs.

Authors:  J Posnett; S Jan
Journal:  Health Econ       Date:  1996 Jan-Feb       Impact factor: 3.046

4.  Perspectives in economic evaluation.

Authors:  S Byford; J Raftery
Journal:  BMJ       Date:  1998-05-16

5.  Costs and cost-minimisation analysis.

Authors:  R Robinson
Journal:  BMJ       Date:  1993-09-18
  5 in total
  33 in total

Review 1.  Using cost effectiveness information.

Authors:  A Briggs; A Gray
Journal:  BMJ       Date:  2000-01-22

2.  National audit of the management of peritonsillar abscess.

Authors:  H M Mehanna; L Al-Bahnasawi; A White
Journal:  Postgrad Med J       Date:  2002-09       Impact factor: 2.401

Review 3.  The impact of disease stage on direct medical costs of HIV management: a review of the international literature.

Authors:  Adrian Levy; Karissa Johnston; Lieven Annemans; Andrea Tramarin; Julio Montaner
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 4.  Opportunity cost in the evaluation of surgical innovations: a case study of laparoscopic versus open colectomy.

Authors:  Abhishek Chatterjee; Lilian Chen; Elie A Goldenberg; Harold T Bae; Samuel R G Finlayson
Journal:  Surg Endosc       Date:  2009-11-13       Impact factor: 4.584

5.  Rethinking How We Measure Costs in Implementation Research.

Authors:  Todd H Wagner
Journal:  J Gen Intern Med       Date:  2020-10-26       Impact factor: 5.128

Review 6.  Inpatient silver sulphadiazine versus outpatient nanocrystalline silver models of care for pediatric scald burns: A value analysis.

Authors:  Claudia Malic; Cynthia Verchere; Jugpal S Arneja
Journal:  Plast Surg (Oakv)       Date:  2014       Impact factor: 0.947

7.  Cost-benefit Analysis of Maintaining a Fully Stocked Malignant Hyperthermia Cart versus an Initial Dantrolene Treatment Dose for Maternity Units.

Authors:  Phi T Ho; Brendan Carvalho; Eric C Sun; Alex Macario; Edward T Riley
Journal:  Anesthesiology       Date:  2018-08       Impact factor: 7.892

8.  Opportunity cost and COVID-19: A perspective from health economics.

Authors:  Mario J Olivera
Journal:  Med J Islam Repub Iran       Date:  2020-12-29

9.  Can choices between alternative hip prostheses be evidence based? a review of the economic evaluation literature.

Authors:  Charlotte Davies; Paula Lorgelly; Ian Shemilt; Miranda Mugford; Keith Tucker; Alex Macgregor
Journal:  Cost Eff Resour Alloc       Date:  2010-10-29

10.  Assessing the opportunity costs of patients with multidrug-resistant organisms in hospitals.

Authors:  Claudia Hübner; Walter Ried; Steffen Flessa
Journal:  Eur J Health Econ       Date:  2017-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.